Oncomutations as biomarkers of cancer risk

Environmental and Molecular Mutagenesis

Volumn 51, Issue 8-9, 2010, Pages 836-850

  Parsons, Barbara L ^a   Myers, Meagan B ^a   Meng, Fanxue ^a   Wang, Yiying ^a   McKinzie, Page B ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Carcinogenesis; Dose response assessment; K Ras; Mutation; Mutation detection; Risk assessment

Indexed keywords

BENZO[A]PYRENE; BIOLOGICAL MARKER; CETUXIMAB; ERLOTINIB; FLUOROURACIL; GEFITINIB; IMATINIB; LEVAMISOLE; MUTAGENIC AGENT; PANITUMUMAB; TUMOR MARKER;

ALLELE; BIOASSAY; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; CODON; COLON MUCOSA; COLORECTAL CANCER; COLORECTAL TUMOR; DOSE RESPONSE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENOTYPE; HUMAN; LIVER TUMOR; LUNG; LUNG ADENOMA; LUNG NON SMALL CELL CANCER; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE; ONCOGENE K RAS; POINT MUTATION; PROGNOSIS; REVIEW; RISK ASSESSMENT; RODENT; SKIN TUMOR; TUMOR SUPPRESSOR GENE; ANIMAL; GENETICS; MUTATION; NEOPLASM; RISK FACTOR;

RODENTIA;

ANIMALS; HUMANS; MUTATION; NEOPLASMS; ONCOGENES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 78349259232     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20600     Document Type: Review

References (85)

1. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. 2008. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634.
2. Andreyev HJN, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, O'Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij AF, Arends JW, Andersen SN, Lovig T, Breivik J, Gaudernack G, Clausen OP, De Angelis PD, Meling GI, Rognum TO, Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ, Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D, Fox JC, Al-Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA, Wadler S, Malik S, Krtolica K, Urosevic N. 2001. Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study. Br J Cancer 85: 692-696.
3. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A. 2007. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67: 2643-2648.
4. Bielas JH, Loeb LA. 2005a. Mutator phenotype in cancer: Timing and perspectives. Environ Mol Mutagen 45: 206-213.
5. Bielas JH, Loeb LA. 2005b. Quantification of random genomic mutations. Nat Methods 2: 285-290.
6. Black HS, DeGruijl FR, Forbes PD, Cleaver JE, Ananthaswamy HN, DeFabo EC, Ullrich SE, Tyrrell RM. 1997. New trends in photobiology (invited review). Photocarcinogenesis: An overview. J Photochem Photobiol B 40: 29-47.
7. Bos JL. 1988. The ras gene family and human carcinogenesis. Mutat Res 195: 255-271.
8. Carton T, Tan XD, Hartemann P, Joyeux M. 2007. Use of genotypic selection to detect P53 codon 273 CGT>CTT transversion: Application to an occupationally exposed population. Int J Hyg Environ Health 210: 69-77.
9. Cha RS, Zarbl H, Keohavong P, Thilly WG. 1992. Mismatch amplification mutation assay (MAMA): Application to the c-H-ras gene. PCR Methods Appl 2: 12-20.
10. Cha RS, Thilly WG, Zarbl H. 1994. N-nitroso-N-methylurea-induced rat mammary tumors arise from cells with preexisting oncogenic Hras1 gene mutations. Proc Natl Acad Sci USA 91: 3749-3753.
11. Chen T, Mittelstaedt RA, Aidoo A, Hamilton LP, Beland FA, Casciano DA, Heflich RH. 2001a. Comparison of hprt and lacl mutant frequency with DNA adduct formation in N-Hydroxy-2-acetylaminofluorene-treated big blue (registered trademark) rats. Environ Mol Mutagen 37: 195-202.
12. Chen T, Mittelstaedt RA, Shelton SD, Balachandra Dass S, Manjanatha MG, Casciano DA, Heflich RH. 2001b. Gene- and tissue-specificity of mutation in big blue (registered trademark) rats treated with the hepatocarcinogen N-Hydroxy-2-acetylaminofluorene. Environ Mol Mutagen 37: 203-214.
13. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboue R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P, Frebourg T. 2007. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96: 1166-1169.
14. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. 2008. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26: 5705-5712.
15. Duggan BJ, Gray SB, McKnight JJ, Watson CJ, Johnston SR, Williamson KE. 2004. Oligoclonality in bladder cancer: The implication for molecular therapies. J Urol 171: 419-425.
16. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. 2000. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355: 1745-1750.
17. Fearon E, Vogelstein B. 1990. A genetic model for colorectal tumorigenesis. Cell 61: 759-767.
18. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, Menzies A, Teague JW, Futreal PA, Stratton MR. 2008. The catalogue of somatic mutations in cancer (COSMIC). Curr Prot Hum Genet 57: 10.11.1-10.11.26.
19. Fox JC, England J, White P, Ellison G, Callaghan K, Charlesworth NR, Hehir J, McCarthy TL, Smith-Ravin J, Talbot IC, Snary D, Northover JM, Newton CR, Little S. 1998. The detection of K-ras mutations in colorectal cancer using amplification-refactory mutation system. Br J Cancer 77: 1267-1274.
20. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L. 2007. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97: 1139-1145.
21. Going JJ. 2003. Epithelial carcinogenesis: challenging monoclonality. J Pathol 200: 1-3.
22. Grady WM. 2005. Epigenetic events in the colorectum and in colon cancer. Biochem Soc Trans 33: 684-688.
23. Hanahan D, Weinberg RB. 2000. The hallmarks of cancer. Cell 100: 57-70.
24. Heim S, Teixeira MAR, Pandis N. 2001. Are some breast carcinomas polyclonal in origin? J Pathol 194: 395-397.
25. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA. 2003. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342-4349.
26. Jarabek AM, Pottenger LH, Andrews LS, Casciano D, Embry MR, Kim JH, Preston RJ, Reddy MV, Schoeny R, Shuker D, Skare J, Swenberg J, Williams GM, Zeiger E. 2009. Creating context for the use of DNA adduct data in cancer risk assessment. I. Data organization. Crit Rev Toxicol 39: 659-678.
27. Jenkins GJS, Suzen HS, Sueiro RA, Parry JM. 1999. The restriction site mutation assay: A review of the methodology development and the current status of the technique. Mutagen 14: 439-448.
28. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. 2008. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765.
29. Keohavong P, Zhu D, Melacrinos AC, DeMichele MAA, Wyeant RJ, Luketich JD, Testa JR, Fedder M, Siegrifed JM. 1997. Detection of low-fraction K-ras mutations in primary lung tumors using a sensitive method. Int J Cancer 74: 162-170.
30. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA3rd, Poplin EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ. 2007. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25: 3230-3237.
31. Khrapko K, Coller HA, Li-Sucholeiki XC, Andre PC, Thilly WG. 2001. High resolution analysis of point mutations by constant denaturant capillary electrophoresis (CDCE). Methods Mol Biol (Clifton, NJ) 163: 57-72.
32. King-Herbert A, Thayer K. 2006. NTP workshop: Animal models for the NTP rodent cancer bioassay: Stocks and strains-Should we switch? Toxicol Pathol 34: 802-805.
33. Kobayashi S., Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. 2005. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792.
34. Lambert IB, Singer TM, Boucher SE, Douglas GR. 2005. Detailed review of transgenic rodent mutation assays. Mutation Res 590: 1-280.
35. Lehman TA, Scott F, Seddon M, Kelly K, Dempsey EC, Wilson VL, Mulshine JL, Modali R. 1996. Detection of K-ras oncogene mutations by polymerase chain reaction-based ligase chain reaction. Anal Biochem 239: 153-159.
36. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, Andre T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P. 2008. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-379.
37. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P. 2006. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995.
38. Lin HJL, Zuo T, Chao JR, Peng Z, Asamoto LK, Yamashita SS, Huang THM. 2009. Seed in soil, with an epigenetic view. Biochim Biophys Acta 1790: 920-924.
39. Lu J, Jiang C, Mitrenga T, Cutter G, Thompson HJ. 1998. Pathogenetic characterization of 1-methyl-1-nitrosourea-induced mammary carcinomas in the rat. Carcinogenesis 19: 223-227.
40. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
41. Manjanatha MG, Li EE, Fu PP, Heflich RH. 1996. H- and K-ras mutational profiles in chemically induced liver tumors from B6C3F1 and CD-1 mice. J Toxicol Environ Health 47: 195-208.
42. Maronpot RR, Fox T, Malarkey DE, Goldsworthy TL. 1995. Mutations in the ras proto-oncogene: Clues to etiology and molecular pathogenesis of mouse liver tumors. Toxicology 101: 125-156.
43. Mass MJ, Jeffers AJ, Ross JA, Nelson G, Galati AJ, Stoner GD, Nesnow S. 1993. Ki-ras oncogene mutations in tumors and DNA adducts formed by benz[j]aceanthrylene and benzo[a]pyrene in the lungs of strain A/J mice. Mol Carcinog 8: 186-192.
44. Masumura K, Nohmi T. 2009. Spontaneous mutagenesis in rodents: Spontaneous gene mutations identified by neutral reporter genes in gpt delta transgenic mice and rats. J Health Sci 55: 40-49.
45. McKinzie PB, Delongchamp RR, Heflich RH, Parsons BL. 2001. Prospects for applying genotypic selection of somatic oncomutation to chemical risk assessment. Mutat Res 489: 47-78.
46. McKinzie PB, Parsons BL. 2002. Detection of rare K-ras codon 12 mutations using allele-specific competitive blocker PCR. Mutat Res 517: 209-220.
47. McKinzie PB, Delongchamp RR, Chen T, Parsons BL. 2006. ACB-PCR measurement of K-ras codon 12 mutant fractions in livers of Big Blue rats treated with N-hydroxy-2-acetylaminofluorene. Mutagen 21: 391-397.
48. McKinzie PB, Delongchamp RR, Parsons BL. 2007. Accumulation of K-Ras mutation in rat colon after azoxymethane exposure. Environ Mol Mutagen 48: 587.
49. Melnikova VO, Ananthaswamy HN. 2005. Cellular and molecular events leading to the development of skin cancer. Mutat Res 571: 91-106.
50. Meng F, Bermudez E, Andersen ME, Clewell HJIII, McKinzie PB, Parsons BL. 2010a. Measurement of tumor-associated mutations in the nasal mucosa of rats exposed to varying doses of formaldehyde. Regul Toxicol Pharmacol doi:10.1016/j.yrtph.2010.03.007.
51. Meng F, Knapp GW, Green T, Ross JA, Parsons BL. 2010b. K-Ras mutant fraction in A/J mouse lung increases as a function of benzo[a]pyrene dose. Environ Mol Mutagen 51: 146-155.
52. Moore MM, Heflich RH, Haber LT, Allen BC, Shipp AM, Kodell RL. 2008. Analysis of in vivo mutation data can inform cancer risk assessment. Regul Toxicol Pharmacol 51: 151-161.
53. Morgan C, Jenkins GJS, Ashton T, Griffiths AP, Baxter JN, Parry EM, Parry JM. 2003. Detection of p53 mutations in precancerous gastric tissue. Br J Cancer 89: 1314-1319.
54. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A. 2005. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study. Lancet Oncol 6: 279-286.
55. Neri M, Cesario A, Granone P, Dominioni L, Puntoni R, D'Angelillo RM, Russo P. 2006. Prognostic role of K-Ras mutations in non-small cell lung cancer: Still an issue for open debate. Lung Cancer 53: 393-395; author reply 397-398.
56. Nesnow S, Ross JA, Stoner GD, Mass MJ. 1995. Mechanistic linkage between DNA adducts, mutations in oncogenes and tumorigenesis of carcinogenic environmental polycyclic aromatic hydrocarbons in strain A/J mice. Toxicology 105: 403-413.
57. Orou A, Fechner B, Utermann G, Menzel HJ. 1995. Allele-specific competitive blocker PCR: A one-step method with applicability to pool screening. Human Mutat 6: 163-169.
58. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. 2004. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
59. Parsons BL. 2008. Many different tumor types have polyclonal origin: Evidence and implications. Mutat Res 659: 232-247.
60. Parsons BL, Heflich RH. 1997. Genotypic selection methods for the direct analysis of point mutations. Mutat Res 387: 97-121.
61. Parsons BL, Meng F. 2009. K-RAS mutation in the screening, prognosis and treatment of cancer. Biomarkers Med 3: 757-769.
62. Parsons BL, Beland FA, Von Tungeln LS, Delongchamp RR, Fu PP, Heflich RH. 2005. Levels of 4-aminobiphenyl-induced somatic H-ras mutation in mouse liver DNA correlate with potential for liver tumor development. Mol Carcinog 42: 193-201.
63. Parsons BL, Marchant-Miros KE, Delongchamp RR, Verkler TL, Patterson TA, Broadwater RJ, Mckinzie PB, Kim LT. 2010. ACB-PCR quantification of K-RAS codon 12 GAT and GTT mutant fraction in colon tumor and non-tumor tissue. Cancer Invest 28: 364-375.
64. Pourzand C, Cerutti P. 1993. Genotypic mutation analysis by RFLP/PCR. Mutat Res 288: 113-121.
65. Preston RJ. 2000. Response to Klaunig J.E. et al.'s "epigenetic mechanisms of chemical carcinogenesis." Hum Exp Toxicol 19: 569-570.
66. Ross JA, Nelson GB, Wilson KH, Rabinowitz JR, Galati A, Stoner GD, Nesnow S, Mass MJ. 1995. Adenomas induced by polycyclic aromatic hydrocarbons in strain A/J mouse lung correlate with time-integrated DNA adduct levels. Cancer Res 55: 1039-1044.
67. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazzucchelli L, Lamba S, Veronese S, Frattini M, Bardelli A, Siena S. 2009a. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 4: e7287.
68. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. 2009b. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69: 1851-1857.
69. Sieben NL, Roemen GMJM, Oosting J, Fleuren GJ, van Engeland M, Prat J. 2006. Clonal analysis favors a monoclonal origin for serous borderline tumours with peritoneal implants. J Pathol 210: 405-411.
70. Sobels FH. 1977. Some problems associated with the testing for environmental mutagens and a perspective for studies in "comparative mutagenesis". Mutat Res 46: 245-260.
71. Song HL, Jenkins GJS, Ashby J, Tinwell H, Parry JM. 2001. The application of the restriction site mutation assay to compare 1-ethyl-1-nitrosourea-induced mutations between the endogenous p53 gene and the transgenic LacZ gene in MutaMouse testes. Mutagen 16: 59-64.
72. Sudo H, Li-Sucholeiki X-C, Marcelino LA, Gruhl AN, Zarbl H, Willey JC, Thilly WG. 2006. Distributions of five common point mutants in the human tracheal-bronchial epithelium. Mutat Res 596: 113-127.
73. Thilly WG. 2003. Have environmental mutagens caused oncomutations in people? Nat Genet 34: 255-259.
74. Thirlwell C, Will OCC, Domingo E, Graham TA, McDonald SAC, Oukrif D, Jeffrey R, Gorman M, Rodriguez-Justo M, Chin-Aleong J, Clark SK, Novelli MR, Jankowski JA, Wright NA, Tomlinson IP, Leedham SJ. 2010. Clonality assessment and clonal ordering of individual neoplastic crypts shows polyclonality of colorectal adenomas. Gastroenterology 138: 1441-1454. 1454.e1-7.
75. Verkler TL, Delongchamp RR, Couch LH, Miller BJ, Warbritton A, Mellick PW, Howard PC, Parsons BL. 2008a. Populations of p53 codon 270 CGT to TGT mutant cells in SKH-1 mouse skin tumors induced by simulated solar light. Mol Carcinog 47: 822-834.
76. Verkler TL, Delongchamp RR, Miller BJ, Webb PJ, Howard PC, Parsons BL. 2008b. Simulated solar light-induced p53 mutagenesis in SKH-1 mouse skin: a dose-response assessment. Mol Carcinog 47: 599-607.
77. Von Tungeln LS, Yi P, Bucci TJ, Samokyszyn VM, Chou MW, Kadlubar FF, Fu PP. 2002. Tumorigenicity of chloral hydrate, trichloroacetic acid, trichloroethanol, malondialdehyde, 4-hydroxy-2-nonenal, crotonaldehyde, and acrolein in the B6C3F1 neonatal mouse. Cancer Lett 185: 13-19.
78. Wilson VL, Wei Q, Wade KR, Chisa M, Bailey D, Kanstrup CM, Yin X, Jackson CM, Thompson B, Lee WR. 1999. Needle-in-a-haystack detection and identification of base substitution mutations in human tissues. Mutat Res 406: 79-100.
79. Wilson VL, Yin X, Thompson B, Wade KR, Watkins JP, Wei Q, Lee WR. 2000. Oncogenic base substitution mutations in circulating leukocytes of normal individuals. Cancer Res 60: 1830-1834.
80. Winder T, Scheithauer W, Lang A. 2009. K-ras mutations and cetuximab in colorectal cancer. N Engl J Med 360: 834-835; author reply 835-836.
81. Yan Y, Wang Y, Tan Q, Lubet RA, You M. 2005. Efficacy of deguelin and silibinin on benzo(a)pyrene-induced lung tumorigenesis in A/J mice. Neoplasia 7: 1053-1057.
82. Yan Y, Wang Y, Tan Q, Hara Y, Yun TK, Lubet RA, You M. 2006. Efficacy of polyphenon E, red ginseng, and rapamycin on benzo(a)pyrene-induced lung tumorigenesis in A/J mice. Neoplasia 8: 52-58.
83. You M, Wang Y, Stoner G, You L, Maronpot R, Reynolds SH, Anderson M. 1992. Parental bias of Ki-ras oncogenes detected in lung tumors from mouse hybrids. Proc Natl Acad Sci USA 89: 5804-5808.
84. You YH, Szabo PE, Pfeifer GP. 2000. Cyclobutane pyrimidine dimers form preferentially at the major p53 mutational hotspot in UVB-induced mouse skin tumors. Carcinogenesis 21: 2113-2117.
85. Zhang S, Glickman BW, De Boer JG. 2001. Spontaneous mutation of the lacl transgene in rodents: Absence of species, strain, and insertion-site influence. Environ Mol Mutagen 37: 141-146.